Safety of human papillomavirus vaccines: a review
KK Macartney, C Chiu, M Georgousakis… - Drug safety, 2013 - Springer
Vaccination to prevent human papillomavirus (HPV)-related infection leading to cancer,
particularly cervical cancer, is a major public health breakthrough. There are currently two …
particularly cervical cancer, is a major public health breakthrough. There are currently two …
Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition …
LE Markowitz, S Hariri, C Lin, EF Dunne… - The Journal of …, 2013 - academic.oup.com
Background. Human papillomavirus (HPV) vaccination was introduced into the routine
immunization schedule in the United States in late 2006 for females aged 11 or 12 years …
immunization schedule in the United States in late 2006 for females aged 11 or 12 years …
Towards the eradication of HPV infection through universal specific vaccination
P Crosignani, A De Stefani, GM Fara, AM Isidori… - BMC public health, 2013 - Springer
Abstract Background The Human Papillomavirus (HPV) is generally recognized to be the
direct cause of cervical cancer. The development of effective anti-HPV vaccines, included in …
direct cause of cervical cancer. The development of effective anti-HPV vaccines, included in …
Clinical trial experience with prophylactic human papillomavirus 6/11/16/18 vaccine in young black women
LR Clark, ER Myers, W Huh, EA Joura… - Journal of adolescent …, 2013 - Elsevier
PURPOSE: Human papillomavirus (HPV) is the causative agent of cervical cancer. Black
women are disproportionally diagnosed and have higher mortality from cervical cancer in …
women are disproportionally diagnosed and have higher mortality from cervical cancer in …
Human papillomavirus vaccines six years after approval
AR Shaw - Annual review of medicine, 2013 - annualreviews.org
Human Papillomavirus Vaccines Six Years After Approval | Annual Reviews Menu Publications
AZ Journal Information About Subscribe Give Personal Register/Sign-in 0 Cart Help Journal …
AZ Journal Information About Subscribe Give Personal Register/Sign-in 0 Cart Help Journal …
[PDF][PDF] Human papillomavirus vaccine and the ovary: the need for research
DT Little - Proceedings of the 18th World Congress on …, 2013 - academia.edu
New onset of menstrual disturbance and oligomenorrhoea commencing four months after
quadrivalent human papillomavirus vaccine (HPV4) and proceeding to premature ovarian …
quadrivalent human papillomavirus vaccine (HPV4) and proceeding to premature ovarian …
Public health surveillance for vaccine adverse events
JK Iskander, Y Zheteyeva - Infectious Disease Surveillance, 2013 - Wiley Online Library
Prelicensure clinical trials establish vaccine efficacy and safety. However, they are generally
not large enough to detect rare or unusual vaccine adverse events. Therefore, postlicensure …
not large enough to detect rare or unusual vaccine adverse events. Therefore, postlicensure …
[PDF][PDF] Revisión del Programa de Vacunación frente a Virus del Papiloma Humano en España
P de Programa, R de Vacunaciones - 2013 - gestor.camfic.cat
La prevalencia global de infección por el virus del papiloma humano (VPH) en España en el
grupo de edad de 18-65 años es de un 14, 3%, ascendiendo a medida que desciende la …
grupo de edad de 18-65 años es de un 14, 3%, ascendiendo a medida que desciende la …
[引用][C] La vacunació contra el virus del papil· loma humà (VPH) a Catalunya: Actualització 2013
D de Salut - 2013 - Agència de Salut Pública de …